+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Hepatitis B - Pipeline Review, H2 2020

  • ID: 5229490
  • Drug Pipelines
  • November 2020
  • Region: Global
  • 575 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Abhelix LLC
  • Atea Pharmaceuticals Inc
  • Decoy Biosystems Inc
  • HEC Pharm Co Ltd
  • MYR GmbH
  • Sinovac Biotech Ltd
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Pipeline Review, H2 2020, provides an overview of the Hepatitis B (Infectious Disease) pipeline landscape.

Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus. Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting and abdominal pain. Risk factors include age, severe kidney disease, hemophilia, share needles during drug use and born to a hepatitis-b infected mother. Treatment includes antiviral drugs.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Hepatitis B - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Hepatitis B (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis B (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis B and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 7, 35, 34, 5, 86, 40 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 1, 12 and 6 molecules, respectively.

Hepatitis B (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis B (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Hepatitis B (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hepatitis B (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hepatitis B (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis B (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hepatitis B (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hepatitis B (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abhelix LLC
  • Atea Pharmaceuticals Inc
  • Decoy Biosystems Inc
  • HEC Pharm Co Ltd
  • MYR GmbH
  • Sinovac Biotech Ltd
Introduction
  • Hepatitis B- Overview
  • Hepatitis B- Therapeutics Development
  • Hepatitis B- Therapeutics Assessment
  • Hepatitis B- Companies Involved in Therapeutics Development
  • Hepatitis B- Drug Profiles
  • Hepatitis B- Dormant Projects
  • Hepatitis B- Discontinued Products
  • Hepatitis B- Product Development Milestones
Appendix

List of Tables
  • Number of Products under Development for Hepatitis B, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Stage and Target, H2 2020
  • Number of Products by Stage and Mechanism of Action, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Hepatitis B - Pipeline by Abhelix LLC, H2 2020
  • Hepatitis B - Pipeline by Ai-biopharma SAS, H2 2020
  • Hepatitis B - Pipeline by AiCuris GmbH & Co KG, H2 2020
  • Hepatitis B - Pipeline by AIMM Therapeutics BV, H2 2020
  • Hepatitis B - Pipeline by Akshaya Bio Inc, H2 2020
  • Hepatitis B - Pipeline by Aligos Therapeutics Inc, H2 2020
  • Hepatitis B - Pipeline by AlloVir Inc, H2 2020
  • Hepatitis B - Pipeline by AlphaMab Co Ltd, H2 2020
  • Hepatitis B - Pipeline by Alphamab Oncology, H2 2020
  • Hepatitis B - Pipeline by Altimmune Inc, H2 2020
  • Hepatitis B - Pipeline by Antios Therapeutics Inc, H2 2020
  • Hepatitis B - Pipeline by Apros Therapeutics Inc, H2 2020
  • Hepatitis B - Pipeline by Arbutus Biopharma Corp, H2 2020
  • Hepatitis B - Pipeline by Arcturus Therapeutics Ltd, H2 2020
  • Hepatitis B - Pipeline by Ark Biosciences Inc, H2 2020
  • Hepatitis B - Pipeline by Ascentage Pharma Group International, H2 2020
  • Hepatitis B - Pipeline by Ascletis Pharma Inc, H2 2020
  • Hepatitis B - Pipeline by Assembly Biosciences Inc, H2 2020
  • Hepatitis B - Pipeline by Atea Pharmaceuticals Inc, H2 2020
  • Hepatitis B - Pipeline by Aucta Pharmaceuticals LLC, H2 2020
  • Hepatitis B - Pipeline by Avalia Immunotherapies Ltd, H2 2020
  • Hepatitis B - Pipeline by Beijing Advaccine Biotechnology Company Ltd, H2 2020
  • Hepatitis B - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H2 2020
  • Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2020
  • Hepatitis B - Pipeline by Benitec Biopharma Inc, H2 2020
  • Hepatitis B - Dormant Projects, H2 2020
  • Hepatitis B - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Hepatitis B, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Universities/Institutes, H2 2020
  • Number of Products by Top 10 Targets, H2 2020
  • Number of Products by Stage and Top 10 Targets, H2 2020
  • Number of Products by Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
  • Number of Products by Top 10 Molecule Types, H2 2020
  • Number of Products by Stage and Top 10 Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • Abhelix LLC
  • Ai-biopharma SAS
  • AiCuris GmbH & Co KG
  • AIMM Therapeutics BV
  • Akshaya Bio Inc
  • Aligos Therapeutics Inc
  • AlloVir Inc
  • AlphaMab Co Ltd
  • Alphamab Oncology
  • Altimmune Inc
  • Antios Therapeutics Inc
  • Apros Therapeutics Inc
  • Arbutus Biopharma Corp
  • Arcturus Therapeutics Ltd
  • Ark Biosciences Inc
  • Ascentage Pharma Group International
  • Ascletis Pharma Inc
  • Assembly Biosciences Inc
  • Atea Pharmaceuticals Inc
  • Aucta Pharmaceuticals LLC
  • Avalia Immunotherapies Ltd
  • Beijing Advaccine Biotechnology Company Ltd
  • Beijing Kawin Technology Share-Holding Co Ltd
  • Beijing Minhai Biotechnology Co Ltd
  • Benitec Biopharma Inc
  • Biological E Ltd
  • Biomics Biopharma Ltd
  • BioNet-Asia Co Ltd
  • Biotron Ltd
  • Bolder Biotechnology Inc
  • Bonac Corp
  • Brandenburg Antiinfektiva GmbH
  • Brickell Biotech Inc
  • BrightGene Bio-Medical Technology Co Ltd
  • Bukwang Pharmaceutical Co Ltd
  • Cadila Healthcare Ltd
  • CaroGen Corp
  • Casterbridge Pharmaceuticals Inc
  • Chengdu Hyperway Pharmaceuticals
  • Chia Tai Tianqing Pharmaceutical Group Co Ltd
  • Chong Kun Dang Pharmaceutical Corp
  • Chongqing Zhifei Biological Products Co Ltd
  • Cinkate Corp
  • CN Bio Innovations Ltd
  • Cocrystal Pharma Inc
  • Collaborations Pharmaceuticals Inc
  • Cytocom Inc
  • CyTuVax BV
  • Decoy Biosystems Inc
  • DelSiTech Ltd
  • Dicerna Pharmaceuticals Inc
  • Door Pharmaceuticals LLC
  • Dynavax Technologies Corp
  • Elixiron Immunotherapeutics Inc
  • Enanta Pharmaceuticals Inc
  • Enochian Biosciences Inc
  • Enyo Pharma SA
  • Etna Biotech Srl
  • Excision BioTherapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Finch Therapeutics Group
  • FortuneRock (China) Ltd
  • Fujian Cosunter Pharmaceutical Co Ltd
  • GC Pharma
  • GemVax & KAEL Co Ltd
  • GeneCure LLC
  • GeneScience Pharmaceuticals Co Ltd
  • GeoVax Labs Inc
  • Gilead Sciences Inc
  • Ginkgo Tree Pharmaceutical (Suzhou) Co Ltd
  • GlaxoSmithKline Plc
  • Golden Biotechnology Corp
  • Guangdong East Sunshine Pharmaceutical Co Ltd
  • Guangxi Hebabiz Pharmaceutical Co Ltd
  • Guangzhou Yipinhong Pharmaceutical Co Ltd
  • HEC Pharm Co Ltd
  • Hepion Pharmaceuticals Inc
  • Huahui Anjian (Beijing) Biotechnology Co Ltd
  • Humabs BioMed SA
  • Huons Co Ltd
  • ImmuneMed Inc
  • Immunocore Ltd
  • Immunotope Inc
  • Innovent Biologics Inc
  • Inovio Pharmaceuticals Inc
  • Ionis Pharmaceuticals Inc
  • ISA Pharmaceuticals BV
  • ISR Immune System Regulation Holding AB
  • Jiangsu Hansoh Pharmaceutical Group Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Jubilant Therapeutics Inc
  • Kainos Medicine Inc
  • KinoPharma Inc
  • LG Chem Ltd
  • Ligand Pharmaceuticals Inc
  • Lion TCR Pte Ltd
  • Max Biopharma Inc
  • Microbiotix Inc
  • MYR GmbH
  • Novo Medi Sciences Pvt Ltd
  • Nucorion Pharmaceuticals Inc
  • Oncolys BioPharma Inc
  • Palisades Therapeutics
  • PharmaEssentia Corp
  • Precision Biosciences Inc
  • Profarma
  • Profectus BioSciences Inc
  • Protheragen Inc
  • Qilu Pharmaceutical Co Ltd
  • Regeneron Pharmaceuticals Inc
  • Regulus Therapeutics Inc
  • Replicor Inc
  • Resonance Health Ltd
  • Rodos BioTarget GmbH
  • Romark Laboratories LC
  • Samjin Pharm Co Ltd
  • Sclnow Biotechnology Co Ltd
  • Scynexis Inc
  • SFA Therapeutics LLC
  • Shanghai Henlius Biotech Inc
  • Shanghai HEP Pharmaceutical Co Ltd
  • Shanghai Zhimeng Biopharma Inc
  • Shantha Biotechnics Pvt Ltd
  • Shenzhen BinDeBio Ltd
  • Sichuan Kelun Pharmaceutical Co Ltd
  • Silverback Therapeutics Inc
  • Sinovac Biotech Ltd
  • SL VaxiGen Inc
  • Staidson BioPharma Inc
  • Suzhou Ribo Life Sciences Co Ltd
  • Suzhou Zelgen Biopharmaceutical Co Ltd
  • TaiGen Biotechnology Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • TCM Biotech International Corp
  • TeneoBio Inc
  • Tetranov International Inc
  • Theravectys SA
  • THEVAX Genetics Vaccine USA Inc
  • Transgene SA
  • UBI Pharma Inc
  • Vaccitech Ltd
  • Vaxart Inc
  • Vaxine Pty Ltd
  • VBI Vaccines Inc
  • VenatoRx Pharmaceuticals Inc
  • Vir Biotechnology Inc
  • Viravaxx AG
  • Viriom Inc
  • Virion Therapeutics LLC
  • Virocovax
  • ViroStatics SRL
  • VLP Biotech Inc
  • Xi’an Xintong Pharmaceutical Research Co Ltd
  • Yisheng Biopharma Co Ltd
  • Zelluna Immunotherapy AS
  • Zhejiang Bola Atu Pharmaceutical Technology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll